By otakuyassine3@gmail.com 
StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research note published on Friday. The brokerage issued a hold rating on the stock.
A number of other research firms have also weighed in on CTLT. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Catalent currently has an average rating of “Hold” and an average price target of $63.40.
Check Out Our Latest Stock Report on CTLT
Catalent Price Performance
Shares of NYSE:CTLT opened at $63.48 on Friday. The firm has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The company has a 50-day moving average price of $60.89 and a two-hundred day moving average price of $59.62. Catalent has a twelve month low of $41.15 and a twelve month high of $63.50.
Catalent (NYSE:CTLT – Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the business posted ($0.10) earnings per share. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Equities analysts forecast that Catalent will post 0.78 EPS for the current year.
Insider Activity
In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.
Institutional Trading of Catalent
Several hedge funds have recently added to or reduced their stakes in the business. Brooklyn Investment Group bought a new position in Catalent during the 3rd quarter worth approximately $31,000. Sentry Investment Management LLC bought a new stake in Catalent during the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC boosted its position in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its holdings in Catalent by 57.5% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. purchased a new position in shares of Catalent in the third quarter valued at about $73,000.
About Catalent
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Read More
Receive News & Ratings for Catalent Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent and related companies with MarketBeat.com’s FREE daily email newsletter.